144 
Monitoring Stem Cell Research 
• For future clinical use, the tumorigenicity of stem/progenitor tissue 
should be determined. 
• Additionally, immune responses toward the transplanted cells should 
be examined. 
Abraham, E. J., et al., “Insulinotropic hormone glucagons-like peptide- 1 differentia- 
tion of human pancreatic islet-derived progenitor cells into insulin-producing cells," 
Endocrinology 143: 3152-3161 (2002). 
Zulewski, H., et al., "Multipotential Nestin-Positive Stem Cells Isolated From Adult 
Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine and He- 
patic Phenotypes," Diabetes 50: 521-533 (2001). 
^ Assady, S., et al., "Insulin production by human embryonic stem cells," Diabetes 50: 
1691-1697 (2001). 
Zhao, M., et al., "Amelioration of streptozotocin-induced diabetes in mice using hu- 
man islet cells derived from long-term culture in vitro," Transplantation 73: 1454-1460 
( 2002 ). 
Zalzman, M., et al., "Reversal of hyperglycemia in mice using human expandable 
insulin-producing cells differentiated from fetal liver cells, " Proceedings of the National 
Academy of Sciences of the United States of America 100: 7253-7258 (2003). 
For a useful summary of the advantages and limitations of rodent models of diabetes 
see: Atkinson, M. A. and Leiter, E. H., "The NOD mouse model of type 1 diabetes: As 
good as it gets?" Nature Medicine 5: 601-604 (1999). 
Faraci, M., et al., "Severe neurologic complications after hematopoietic stem cell 
transplantation in children," Neurology 59: 1895-1904 (2002). 
Baker, K. S., et al., "New Malignancies After Blood or Marrow Stem-Cell Transplanta- 
tion in Children and Adults: Incidence and Risk Factors," Journal of Clinical Investiga- 
tion 21: 1352-1358 (2003). 
Pursley, W. H., Presentation at the September 4, 2003, meeting of the President’s 
Council on Bioethics, Washington, D.C., available at www.bioethics.gov. 
Okarma, T., Presentation at the September 4, 2003, meeting of the President’s Coun- 
cil on Bioethics, Washington, D.C., aveiilable at www.bioethics.gov. 
See presentations from the Juvenile Diabetes Research Foundation International and 
the Michael J. Fox Foundation at the September 4, 2003, meeting of the President’s 
Council on Bioethics, Washington, D.C., available at www.bioethics.gov. 
See, for example. Carpenter, M. K., et al., “Characterization and Differentiation of 
Human Embryonic Stem Cells," Cloning and Stem Cells 5: 79-88 (2003), and Pittenger, 
M. F. et al., "Multilineage potential of adult human mesenchymal stem cells," Science 
284: 143-147 (1999), and Pittenger, M. F., et al., "Adult mesenchymal stem cells: Poten- 
tial for muscle and tendon regeneration and use in gene therapy, ’’ Journal of Muscu- 
loskeletal and Neuronal Interactions 2: 309-320 (2002). 
Daley, G. Q., et al., “Realistic Prospects for Stem Cell ’Therapeutics,” Hematology 
American Society for Hematology Education Program: 398-418 (2003). 
PRE-PUBLICATION VERSION 
